x

Posted 01 May, 2023

Oncorus, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:ONCR in a 8-K filed on 01 May, 2023.


  On April 30, 2023, the Company's board of directors appointed Theodore (Ted) Ashburn, M.D., Ph.D., the Company's Chief Executive Officer, as principal financial officer and principal accounting officer, effective as of such date.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Oncorus, Inc.
Health Care/Life Sciences • Biotechnology
Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. It develops an immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Andover, MA.
Market Cap
N/A
View Company Details
Oncorus, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

It is with great sadness that Oncorus, Inc. (the "Company") reports the death of its Chief Financial Officer, Richard Wanstall, on April 29, 2023. Mr. Wanstall served as the Company's Chief Financial Officer since May 2022. He will be deeply missed by his friends and colleagues at the Company. 

On April 30, 2023, the Company's board of directors appointed Theodore (Ted) Ashburn, M.D., Ph.D., the Company's Chief Executive Officer, as principal financial officer and principal accounting officer, effective as of such date. Biographical information for Dr. Ashburn is available in the Company's proxy statement filed with the Securities and Exchange Commission on May 13, 2022 in connection with the Company's 2022 annual meeting of stockholders, such information being incorporated herein by reference.